Looking good, page-2

What is developing with Noxopharm, I think, is what GK has demonstrated with Novogen (twice) and with Marshall. Each advance is naturally slow in biopharma, so the only way to maitain momentum is the progression of multiple activities at once. This becomes easier if the core project both advances and generates peripheral projects along the way. Like ion propulsion, we now have collective newsflow from diverse sources to maintain a constant push. Much more to Noxopharm than marketing but I feel we're in competent hands there too.